文献速递妇科

卵巢癌生存的年龄和分期差异:ICBP SurvMark-2 基于人群研究

Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
PubMed 文献 · Gynecol Oncol · 2020-01-28

该研究分析七国21个癌症登记处58,161例2010-2014年确诊卵巢癌女性的数据,随访至2015年底,比较1年和3年年龄别及分期别净生存。结果显示各国分期分布差异较小,3年全年龄净生存45-57%,澳大利亚和挪威最高;老年晚期患者生存国际差异最大。

要点

  • 3年全年龄净生存率范围为45-57%,澳大利亚和挪威最高。
  • 远处转移期比例在65-74岁和75-99岁最高,且各国间差异显著。
  • 最老年组3年年龄别生存率最低(20-34%),65-74岁组各国差异最大。

核心结论

  • 卵巢癌生存存在国际差异,最老年晚期患者差异最大,提示需研究治疗可及性和合并症的影响。

研究设计与样本

  • 基于人群研究,分析七国21个癌症登记处58,161例2010-2014年确诊卵巢癌女性,随访至2015年12月31日。

主要发现

  • 3年全年龄净生存率范围为45-57%,澳大利亚56%和挪威57%最高。
  • 远处转移期比例在65-74岁为72-80%,75-99岁为77-87%,各国间差异显著。
  • 最老年组3年年龄别生存率最低,为20-34%。
  • 65-74岁组3年净生存率各国差异最大,范围为40-60%。
  • 最老年远处转移期患者3年净生存率各国差异显著,爱尔兰12%至挪威24%。

临床怎么用

  • 应关注老年晚期卵巢癌患者的治疗可及性和合并症管理,以缩小国际生存差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries. METHODS: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010-2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach. RESULTS: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with 'distant' stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with 'distant' stage was highest for those aged 65-74 and 75-99 years and varied markedly between countries (range:72-80% and 77-87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20-34%), and women aged 65-74 exhibited the widest variation across countries (3-year NS range: 40-60%). Differences in survival between countries were particularly stark for the oldest age group with 'distant' stage (3-year NS range: 12% in Ireland to 24% in Norway). CONCLUSIONS: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cabasag CJ, Butler J, Arnold M, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study. Gynecol Oncol. 2020. PMID: 32005583. doi:10.1016/j.ygyno.2019.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。